SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

Helius Medical Technologies Inc - Ordinary Shares - Class A

Helius Medical Technologies Inc

HSDT is trending due to positive trial results for its PoNS device in stroke rehabilitation, sparking community excitement about its potential FDA submission under Breakthrough Device Designation. The community is actively discussing the low float and potential for a short squeeze, while some caution about potential dilution. Broader context includes the company's focus on neuromodulation therapies and its existing FDA approval for multiple sclerosis.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending due to its dedicated community and consistent growth over the past nine months, setting new all-time highs. The community is energized by a current buy contest and anticipates increased exposure with an upcoming listing, as well as an airdrop. Many believe $BROKE.X is undervalued and poised for a significant breakout, emphasizing its resilience and potential in the altcoin space.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

aTyr Pharma is trending as traders anticipate the release of Phase 3 trial data for their lead drug, Efzofitimod, with potential implications for treating pulmonary sarcoidosis; the community is discussing possible outcomes and speculating on a short squeeze, while acknowledging the inherent risks of a binary biotech event; some are closely watching for early data leaks or unusual trading patterns, while others are reviewing past trial data and KOL opinions to inform their investment decisions.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia ($NVDA) is trending amid news of China investigating potential antitrust violations related to a past acquisition, sparking concerns about market access and potential penalties. The community debates the significance of this development, with some viewing it as an opportunity to buy the dip while others express concerns about the stock's vulnerability to negative China-related headlines and potential broader market impacts. Despite the uncertainty, some remain optimistic about Nvidia's long-term prospects, citing its leadership in AI and strong fundamentals.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors discuss its high short interest and potential for a squeeze, with some citing the upcoming Rumble Wallet launch and the Northern Data acquisition as possible catalysts. JD Vance's exclusive on the platform and overall ties to prominent figures are also fueling community speculation. Despite some frustration with the stock's performance, bulls remain optimistic about its long-term potential, particularly with its connections to crypto and a shift towards alternative media.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities Inc. ($ASST) is trending due to its recent merger with Strive and a strategic shift towards Bitcoin, sparking discussions of a potential short squeeze. The community is focused on high short interest, borrow fees, and the possibility of forced buy-ins, with many anticipating significant price movement. Some traders are experiencing trading restrictions, while others speculate on the impact of potential dilution from warrants.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending amid excitement surrounding upcoming presentations at the Quantum World Congress and UK regulatory approval for its acquisition of Oxford Ionics. The community is actively debating whether IONQ can achieve a market capitalization similar to that of NVDA, and many are citing the stock's potential for significant long-term gains while some discuss short-term profit taking.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is trending due to positive sentiment around nuclear energy deals and potential entry into the US SMR market. Community members are discussing the UK's commitment to nuclear expansion and anticipating further news from upcoming industry events. Increased defense spending and potential partnerships related to AI data centers are also driving interest in the stock.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla ($TSLA) is trending amid rising Q3 delivery expectations and increased energy storage discussion. Community chatter highlights Barclays raising delivery expectations, robotics potential, and the cult-like following the stock commands. Some caution remains due to ending tax credits and potential bank target revisions.

BlackRock Institutional Trust Company N.A. - iShares Semiconductor ETF

iShares Semiconductor ETF

SOXX is trending due to a mix of factors, including reactions to Nvidia's potential to resume AI chip sales in China and overall optimism in the semiconductor sector. Community discussions revolve around SOXX's technical indicators, potential pullbacks, and strategies involving leveraged ETFs like SOXL and SOXS. Broader market context includes the AI boom, geopolitical tensions, and upcoming earnings reports from major semiconductor companies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Emergent BioSolutions shares rose after the company disclosed that it will supply additional doses of CNJ-016, a treatment used for certain complications of the smallpox vaccine, to the U.S. government.The company’s shares closed 3.8% higher at $6.87 on Tuesday, with shares rising another 3.5% to $7.11 in after-hours trading.The new shipment is part of a long-term deal signed back in 2019 with the Administration for Strategic Preparedness and Response, a branch of the Department of Health and Human Services.&nbsp;CNJ-016 is used to treat uncommon but serious side effects from the smallpox vaccine, such as eczema vaccinatum and progressive vaccinia.&nbsp;It is not intended for&nbsp;the treatment of postvaccinal encephalitis or isolated vaccinia keratitis.&nbsp;The product comes with several safety considerations, including risks of allergic reactions, kidney issues, blood clots, and inaccurate blood sugar readings in some patients due to interference with glucose monitors.This latest modification comes shortly after a separate $62.4 million award on June 23, also from ASPR, for additional supply of Emergent’s botulism antitoxin, BAT.&nbsp;The BAT treatment is used in confirmed or suspected cases of botulism involving multiple neurotoxin types.In a separate update last week, the company expanded its NARCANDirect platform to include Kloxxado Nasal Spray 8 mg, an opioid overdose reversal medication.&nbsp;The online ordering system is available to groups, including first responders, schools, government agencies, and community-based programs focused on naloxone distribution.On Stocktwits, retail sentiment was ‘neutral’ amid ‘normal’ message volume.<a href="https://stocktwits.com/symbol/EBS">Emergent BioSolutions’ stock</a> has risen 33.1% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Emergent BioSolutions Stock Rises After New US Order For Smallpox Complication Therapy

The company also secured a $62.4 million modification to its botulism antitoxin supply contract and recently expanded its NARCANDirect platform to include a new opioid overdose reversal spray.

Equity

5 Broker-Loved Stocks Amid EU Tariff Pause & Consumer Confidence Boost

Zacks.com featured highlights include BrightSpring Health Services, Beyond, Air Canada, HF Sinclair and Emergent BioSolutions

Emergent Biosolutions (EBS) Q1 Earnings Top Estimates

Shares of Emergent BioSolutions plunged more than 8% in after-hours trading on Monday after the company reported a steep revenue drop in the fourth quarter.&nbsp;While Emergent swung to a profit, the earnings beat failed to offset concerns over its shrinking top line.The medical contract development and manufacturing firm posted adjusted net income of $0.05 per diluted share, a sharp reversal from the $0.77 per share loss a year earlier. Analysts had expected a loss of $0.43 per share.&nbsp;However, quarterly revenue fell to $194.7 million from $276.6 million a year ago, well below the consensus estimate of $249.5 million.For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million.&nbsp;For 2025, the company projected revenue of $750 million to $850 million, significantly trailing the $1.11 billion analysts had expected.“We delivered favorable full-year financial results driven by our core products, all the while completing a series of strategic stabilization actions to strengthen our financial position ahead of plan,” CEO Joe Papa said.&nbsp;“This strong foundation enables Emergent to focus on profitable revenue growth and cash generation as we move forward with turnaround activities, a critical phase in our multi-year transformation plan.”Despite the revenue shortfall, retail traders on Stocktwits remained optimistic, with sentiment for EBS ending Monday in the ‘bullish’ zone.&nbsp;Many users focused on the company’s improving profitability rather than its shrinking revenue.&nbsp;One trader compared the current situation to a period before Emergent had its Narcan opioid overdose nasal spray in its portfolio, arguing that profitability was the key factor.<stembedurl>https://stocktwits.com/WinstonSmith33/message/606629996</stembedurl>Another user pointed to CEO Joe Papa’s comments on the earnings call, noting that the company’s 2025 guidance appeared “conservative.”&nbsp;<stembedurl>https://stocktwits.com/GrantDiaz/message/606587312</stembedurl>Some traders speculated that Emergent’s mpox vaccine sales had not yet been factored into the guidance.&nbsp;While the company’s smallpox vaccine has been used for mpox, it has not yet&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/govx-siga-ebs-cmrx-stocks-gain-who-declares-who-public-health-emergency/cJId4JgRge">received</a> formal FDA approval for that indication.<a href="https://stocktwits.com/symbol/EBS">Emergent BioSolutions shares</a> are down more than 28% year-to-date but have more than doubled over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Emergent BioSolutions Stock Sinks As Q4 Revenue Plunges 30%, But Retail Clings To Profit Swing

For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million.

Emergent BioSolutions Stock Sinks As Q4 Revenue Plunges 40%, But Retail Clings To Profit Swing

For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million.


Shares of GeoVax Labs Inc. (<a class="mention" data-mention="$GOVX" data-symbol-id="GOVX" href="https://stocktwits.com/symbol/GOVX" target="_blank">$GOVX</a>), SIGA Technologies Inc. (<a class="mention" data-mention="$SIGA" data-symbol-id="SIGA" href="https://stocktwits.com/symbol/SIGA" target="_blank">$SIGA</a>), and Emergent Biosolutions Inc. (<a class="mention" data-mention="$EBS" data-symbol-id="EBS" href="https://stocktwits.com/symbol/EBS" target="_blank">$EBS</a>) gained in mid-day trading on Friday after the World Health Organisation (WHO) reaffirmed that the ongoing upsurge of mpox remains a public health emergency of international concern (PHEIC).Mpox, formerly called monkeypox, is a disease similar to smallpox caused by a virus.&nbsp;“The decision was based on the rising number and continuing geographic spread of cases, operational challenges in the field, and the need to mount and sustain a cohesive response across countries and partners,” the apex health agency said in a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/WHO/status/1860015125463175343">post</a> on X (formerly Twitter).&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_132250_27d9a22ffc.png" alt="Screenshot 2024-11-22 132250.png">The WHO first declared mpox a PHEIC in August earlier this year because a new strain of the virus, Clade Ib, had spread to countries that had not previously reported any incidences of the disease, like Thailand and Sweden.&nbsp;Shares of GeoVax, currently working on a vaccine for mpox and smallpox, were up nearly 10% in mid-day trading on Friday. The stock has lost 47% of its value this year so far.&nbsp;<stembedurl>https://stocktwits.com/gabbs/message/593724551</stembedurl>Meanwhile, shares of SIGA Technologies Inc. (<a class="mention" data-mention="$SIGA" data-symbol-id="SIGA" href="https://stocktwits.com/symbol/SIGA" target="_blank">$SIGA</a>), developing an investigational drug for treating mpox called tecovirimat (TPOXX),&nbsp; jumped 2.5% after the news.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_134247_8c8f14c041.png" alt="Screenshot 2024-11-22 134247.png">Retail sentiment around the stock improved to ‘bullish’ (60/100) from ‘neutral’ a day ago.&nbsp;SIGA Technologies’ shares have gained 11% this year so far.There was less movement around Emergent Biosolutions Inc. (<a class="mention" data-mention="$EBS" data-symbol-id="EBS" href="https://stocktwits.com/symbol/EBS" target="_blank">$EBS</a>), also working on a vaccine for mpox, which saw a marginal uptick of 0.6% in mid-day trading on Friday.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_134547_d67811671e.png" alt="Screenshot 2024-11-22 134547.png">Retail sentiment around the stock remained in the ‘neutral’ zone with no significant change in chatter.&nbsp;Emergent Biosolutions’ vaccine, approved for smallpox, has also been used as a mpox shot, but the U.S. Food and Drug Administration is yet to approve its application for use against the virus.<stembedurl>https://stocktwits.com/WinstonSmith33/message/593679534</stembedurl>In 2022, the company acquired the rights to a smallpox treatment called Tembexa, which was developed by Chimerix Inc. ($CMRX), for up to $337.5 million plus royalties.Chimerix was up around 0.6% as well during mid-day trading.&nbsp;For updates and corrections email newsroom[at]stocktwits[dot]com.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/agrify-stock-doubles-to-hit-over-1-year-high-after-25-9-m-placement-but-retail-wary-of-short-covering-rally/cJIdTKHRg3">Agrify Stock Doubles To Hit Over 1-Year High After $25.9M Placement, But Retail Wary Of Short-Covering Rally</a>

Mpox, formerly called monkeypox, is a disease similar to smallpox caused by a virus. | Source: Pexels

GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks

Emergent Biosolutions and Chimerix also saw marginal gains after the announcement. 

The S&amp;P 500 Index, a broader gauge of stock market performance, finished the week ended Nov. 8 at a record high amid the euphoria over a decisive win for the Republican Party candidate Donald Trump in the 2024 presidential election.The 30-stock Dow Jones Industrial Average and the tech-heavy Nasdaq Composite also ended in uncharted territory.&nbsp;As the new week unfolds, earnings and economic data will once again dictate sentiment. About 91% of the S&amp;P 500 companies have reported already, and the cumulative earnings growth of S&amp;P 500 companies is now estimated at 5.3%,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://advantage.factset.com/hubfs/Website/Resources%20Section/Research%20Desk/Earnings%20Insight/EarningsInsight_110824.pdf">according</a> to Factset.The first-tier economic data/events for the week include the October consumer and producer price inflation reports, due on Wednesday and Thursday, respectively,&nbsp; the October retail sales report due on Friday and speeches by a slew of Federal Reserve officials.As the new week kickstarts, the following stocks are eliciting the most bullish/bearish reactions from retailers on the Stocktwits platformMost BullishMarathon Digital Holdings, Inc. ($MARA)Bitcoin miner Marathon Digital generated the most bullish sentiment, apparently due to the strength seen in the cryptocurrency space, especially the Bitcoin ($BTC.X). The a<a href="https://stocktwits.com/news-articles/markets/equity/bitcoin-hits-record-high-on-sunday/cJ4gJ3oRax">pex crypto crossed the $80,000 threshold</a> on Sunday and the momentum continued unabated on Monday. Bitcoin rallied past the $81,000 mark early Monday.BlackRock, Inc. ($BLK)Asset manager BlackRock was in the news last Thursday as media reports&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/c811be5f-73aa-4565-8901-f0eacdbad0bc">said</a> the company is in discussions to buy a small equity stake in hedge fund Millennium Management. Millennium is one of the most profitable hedge fund and if the rumors prove to be true, it would mark the first time in the firm’s 35-year history that it is taking an outside investment, Financial Times reportedCoinbase Global, Inc. ($COIN)Cryptocurrency exchange Coinbase may also be riding the crypto strength. In late-October, the company reported an increase in its third-quarter revenue from $623 million in 2023 to $1.13 billion in 2024. But both the earnings per share and revenue trailed expectations due to a muted crypto trading environment.Emergent Biosolutions, Inc. ($EBS)&nbsp;Shares of Emergent Biosolutions, a contract development and manufacturing organization, have picked up some momentum following the company’s quarterly results announced late Wednesday. The stock has tacked on over 31% since then.Netflix, Inc. ($NFLX)Streaming giant Netflix hasn't had any company-specific news or analysts’ action to impact the stock. However, AMC Entertainment Holdings, Inc. ($AMC) said last week its third quarter benefited from a new deal with Netflix for prior seasons of AMC series called the AMC Collection.Most BearishBaidu, Inc. (BIDU)Chinese search giant Baidu drew negative sentiment from retailers. Friday, the stock shed nearly 5% amid muted reaction to additional China stimulus and fears concerning a Trump backlash on overseas companies. Media reports said Baidu will launch its new AI-powered smart glasses at the Baidu World Event in Shanghai on Tuesday. The negative sentiment may also be partly due to investor apprehensions over whether the company can give Meta Platforms, Inc.’s ($META) Ray Ban smart glasses a run for the money.Aurinia Pharmaceuticals, Inc. ($AUPH)Kidney drug company Aurinia failed to attract a buyer after activist hedge fund MKT Capital forced the&nbsp; company to explore strategic initiatives, including a sale. While reporting its financial results last week, the Canadian biotech announced its decision to cut 45% of its workforce in a bid to save cost.Pinduoduo, Inc. ($PDD)General skepticism toward China stocks and domestic competition may have dented sentiment toward Chinese online retailer Pinduoduo.Evolent Health, Inc. ($EVH)Shares of Evolent are languishing at multi-year lows following Friday’s 45%+ plunge in reaction to its lackluster quarterly results. The specialty care management services company that focuses on&nbsp;oncology, cardiology, and musculoskeletal markets in the U.S. was scouting for a buyer earlier this year.Checkpoint Therapeutics, Inc. ($CKPT)Waltham, Massachusetts-based Checkpoint Therapeutics, a clinical-stage,&nbsp;immunotherapy and targeted-oncology company, hasn’t had any stock-moving catalysts.&nbsp;Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/fifth-third-executive-weighs-in-on-election-impact/cJ4ginFRaC">Fifth Third CFO Bryan Preston Sees Trump’s 2024 Presidential Election Win Double-Edged Sword</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

Crypto rally has improved sentiment toward stocks with exposure to them.

10 Stocks Retailers On Stocktwits Are Most Bullish/Bearish About To Start The Week

As the new week unfolds, earnings and economic data will again dictate sentiment. 

Shares of Emergent Biosolutions ($EBS) soared 23% (3 pm ET) Thursday after the company reported strong third-quarter results, lifting retail sentiment.Earnings per share for Q3 came in at $1.37, compared to consensus estimates of $0.10, a whopping 1225.81% difference. Revenues stood at $293.8 million, up from $270.5 million last year, driven by operational improvements. Wall Street had estimated revenues at $290.33 million. In addition, it has raised its FY24 revenue outlook to $1.05B-$1.13B."Through disciplined execution and steady, measurable progress, Emergent's financial position is the strongest it has been since 2021 as evidenced by our favorable third-quarter results," Emergent chief executive, Joe Papa, said in a statement, "We have successfully improved efficiencies and refocused our operations related to customer demand, generated value in our core medical countermeasures and NARCAN Nasal Spray businesses and refinanced our debt leading to increased revenue and cash flow.”Retail sentiment for the stock turned ‘extremely bullish’ from ‘neutral’ a day ago. Meanwhile, message volumes were at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1300/290;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_08_at_1_28_37_AM_1cc65c7185.png" alt="Screenshot 2024-11-08 at 1.28.37 AM.png" width="1300" height="290"><figcaption>EBS Sentiment meter and message volumes on Nov 7 as of 3:05 pm ET</figcaption></figure>Emergent is hoping to capitalize on the ongoing public health crises like the opioid overdose epidemic and the Mpox outbreak. On Thursday, it also named &nbsp;Simon Lowry, M.D., as chief medical officer and head of research and development. Lowry, who was previously CEO at Mysthera Therapeutics, will be responsible for advancing Emergent's strategic scientific roadmap, and will oversee research and development, regulatory affairs, medical affairs, clinical and biostatistics, and patient safety.One Stocktwits user suggested the stock could more than double in value over time, with the recent developments.<stembedurl>https://stocktwits.com/manutd123/message/591609601</stembedurl>Emergent’s stock is up 343.6% year-to-date.For updates and corrections, email newsroom@stocktwits.com &nbsp;

Retail sentiment for the stock turned ‘extremely bullish’| Source: Pixabay

Emergent Biosolutions Stock Soars After Q3 Earnings: Retail Sentiment Strong

Earnings per share for Q3 came in at $1.37, compared to consensus estimates of $0.10.

Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024

Emergent BioSolutions stock rises on mixed Q3 results, improved 2024 guidance, and news of a new trial for mpox treatment in Africa led by the CDC.
read more...

What's Going On With Emergent BioSolutions Stock Wednesday?

Emergent BioSolutions stock is trading higher after the company announced the closing of a $100 million asset-backed revolving loan facility.
read more...

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Current Price	$8.14
Prev Close	$8.23
Open	$8.21
Dividend Yield	0.00%
50-Day Moving Average	$7.69
Beta	2.18
Avg. Volume	1.41M
PE Ratio	3.32

52-Week High	$12.73
52-Week Low	$4.02
Market Capitalization	$434.28M
EPS (Annual)	-$3.60
Price to Book	0.82
Revenue Per Employee	$1.16M
Enterprise Value/EBITDA	N/A

EBS
Emergent Biosolutions Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest EBS News

EBS Emergent Biosolutions Inc